Ypsomed Holding AG - Company Profile
Powered by
All the data and insights you need on Ypsomed Holding AG in one report.
- Save hours of research time and resources with
our up-to-date Ypsomed Holding AG Strategy Report
- Understand Ypsomed Holding AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Ypsomed Holding AG (Ypsomed) is a medical device company that designs, develops and manufactures injection and infusion systems for self-medication and offers related services. It offers autoinjectors, dual chamber pens, and pen injectors. The company also offers services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, pharmaceutical and biotechnology companies. The company's products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. The company has its operations in Australia, Austria, Czechia, Denmark, Finland, France, Germany, India, Italy, the Netherlands, Norway, Sweden, Switzerland, United Kingdom, Belgium, China, Canada, Poland, Spain and the US. Ypsomed is headquartered in Burgdorf, Switzerland.
Ypsomed Holding AG premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Delivery Systems: | Contract manufacturing | Penfine |
Autoinjectors | Design and Development Services | Universal Click |
Pen Injectors | Prototyping | Humatro-Pen |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In October, the company signed a supply agreement with Viridian Therapeutics to customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease. |
2023 | New Products/Services | In October, the company announced new Human Factors services. |
2023 | Contracts/Agreements | In September, the company entered into a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. |
Competitor Comparison
Key Parameters | Ypsomed Holding AG | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Sanofi | Abbott Laboratories |
---|---|---|---|---|---|
Headquarters | Switzerland | United States of America | Switzerland | France | United States of America |
City | Burgdorf | New Brunswick | Basel | Paris | Abbott Park |
State/Province | - | New Jersey | - | Ile-de-France | Illinois |
No. of Employees | 2,200 | 131,900 | 103,605 | 87,994 | 114,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gilbert Achermann | Chairman | Executive Board | 2022 | 59 |
Simon Michel | Director; Chief Executive Officer | Executive Board | 2014 | 46 |
Samuel Kunzli | Chief Financial Officer | Senior Management | 2024 | 60 |
Frank Mengis | Chief Operating Officer | Senior Management | 2015 | 59 |
Nicolas Meyer | Chief Legal Officer | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer